ANGLE PLC Secures European Patent for CellKeep Slide, Reducing Cancer Cell Loss by Over 70%

ANGLE PLC's CellKeep slide reduces cancer cell loss by over 70%, boosting liquid biopsy assay sensitivity and enabling more accurate cancer diagnostics.

author-image
Safak Costu
New Update
ANGLE PLC Secures European Patent for CellKeep Slide, Reducing Cancer Cell Loss by Over 70%

ANGLE PLC Secures European Patent for CellKeep Slide, Reducing Cancer Cell Loss by Over 70%

ANGLE PLC, a liquid biopsy company, has announced that the European Patent Office has granted a European Patent for its innovative CellKeep slide. The CellKeep slide is a proprietary device and method that reduces cancer cell loss by over 70% compared to standard microscopy techniques, significantly increasing assay sensitivity.

The CellKeep slide integrates with ANGLE's Parsortix liquid biopsy system to efficiently capture and preserve intact and viable circulating tumor cells (CTCs) from blood samples. In-house testing has shown that the CellKeep slide can eliminate over 70% of CTC loss experienced when using standard techniques, enhancing the reliability of subsequent analytical processes.

Andrew Newland, Chief Executive Officer of ANGLE, stated, "This is a significant technology advancement for the CTC liquid biopsy field and another step towards enabling biomarker-guided precision medicine for people with cancer."

The CellKeep slide is an integral part of ANGLE's Portrait+ CTC staining kit, which is available for customers to identify and enumerate CTCs harvested using the Parsortix system. ANGLE has also received communication from the United States Patent and Trademark Office indicating that the grant of the equivalent US patent application is imminent.

Why this matters: The CellKeep slide represents a major advancement in liquid biopsy technology, potentially enabling more accurate and reliable cancer diagnostics. This development could lead to improved personalized treatment strategies and better outcomes for cancer patients.

In addition to the CellKeep slide, ANGLE has launched an optimized antibody kit for the Parsortix system, priced at £3,000 for ten samples. These developments are expected to enhance ANGLE's assay portfolio and extend the company's market reach in the rapidly growing liquid biopsy field.

The granting of the European patent and the anticipated US patent for the CellKeep slide reinforces ANGLE's position as a leading innovator in the liquid biopsy market. The company believes that these advancements will play a vital role in enabling biomarker-guided precision medicine for cancer patients, potentially transforming cancer diagnostics and treatment.

Key Takeaways

  • ANGLE's CellKeep slide reduces cancer cell loss by over 70% vs. standard techniques.
  • CellKeep slide integrates with ANGLE's Parsortix liquid biopsy system to capture CTCs.
  • ANGLE received European patent for CellKeep slide, US patent expected soon.
  • CellKeep slide advancement could enable more accurate cancer diagnostics and personalized treatment.
  • ANGLE also launched optimized antibody kit for Parsortix system, expanding its assay portfolio.